Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.

Abstract

PURPOSE:

To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) compared with observation for treating acute central serous chorioretinopathy (CSC).

METHODS:

A retrospective study of 36 patients with acute CSC, including 21 patients treated with anti-VEGF (anti-VEGF group) and 15 patients with observation (observation group). Patients in the anti-VEGF group received a single dose of bevacizumab or ranibizumab at baseline. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) and resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) were assessed. The integrity of the foveal inner segment/outer segment (IS/OS) line at 12 months was also analyzed.

RESULTS:

Resolution of SRF was achieved in 20 of 21 eyes in the anti-VEGF group and in 12 of 15 eyes in the observation group (p = 0.151). Mean BCVA and CFT were not different between the two groups at 12 months (p > 0.05). The amount of change in BCVA, however, differed significantly between the groups (p = 0.044). Final OCT more frequently detected the foveal IS/OS line in the anti-VEGF group than in the observation group (p = 0.012).

CONCLUSIONS:

In terms of BCVA, anti-VEGF and observation only had similar therapeutic effects in acute CSC patients. In some patients, however, the rapid resolution of SRF by anti-VEGF might reduce the risk of photoreceptor degeneration and improve long-term visual acuity.

• Authors: Sang-Uk Park, Seung-Jun Lee, Moosang Kim
• Journal: Korean journal of ophthalmology : KJO (Korean J Ophthalmol) Vol. 28 Issue 4 Pg. 306-13 (Aug 2014) ISSN: 2092-9382 [Electronic] Korea (South)
• PMID: 25120339 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab
• Ranibizumab

Topics

• Acute Disease
• Adult
• Angiogenesis Inhibitors (therapeutic use)
• Bevacizumab (therapeutic use)
• Central Serous Chorioretinopathy (drug therapy, physiopathology)
• Female
• Humans
• Intravitreal Injections
• Male
• Middle Aged
• Observation
• Ranibizumab (therapeutic use)
• Retinal Photoreceptor Cell Inner Segment (pathology)
• Retinal Photoreceptor Cell Outer Segment (pathology)
• Retrospective Studies
• Subretinal Fluid (drug effects)
• Tomography, Optical Coherence
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity